Gross price differences between the two ophthalmic drugs. France wants to imitate Italy and the Pharmaceutical Industries Association calls the EU into question. The issue of healthcare costs and that of patient safety. New therapeutic indications
by MAURIZIO PAGANELLI 10 July 2014 – La Repubblica.it Health
THE story of the drug Lucentis for senile macular degeneration BECOMES a European case (cost 902 euros, but effective with discounts of around 600 euros per vial) and of his "alternative" 10 or 30 times cheaper,Avastin, an anti-cancer used off-label, i.e. outside its specific therapeutic indications and not authorized for ofta use
